Effect of Anti-CD303 Antibodies in Autoimmune Diseases

Study Overview
=================
Brief Summary
-----------------
The pathogenic role of type I interferons (IFNs) in the development of different autoimmune diseases has been extensively described in the literature. Since plasmacytoid dendritic cells (pDCs) are the main source of type I IFNs, there is evidence of the involvement of pDCs in autoimmune diseases. The CD303 surface protein (also called BDCA-2) is specifically expressed by the pDCs. The hypothesis leading to the realization of this study is to observe, in vitro, an inhibition of the secretion of the type I IFNs by pDCs in the peripheral blood in patients with autoimmune disease, thanks to the action of the anti-CD303 antibody Developed by the LFB Group, which could reduce the inflammatory response and improve patients with autoimmune disease

Official Title
-----------------
Effect of Monoclonal Anti-cd303 on the Inhibition of Type I Interferon Secretion in the Peripheral Blood of Patients With Autoimmune Diseases

Conditions
-----------------
Immune Disease

Intervention / Treatment
-----------------
* Biological: Monoclonal anti-cd303 antibody


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have the ability to understand the requirements of the study, provide written informed consent, and comply with the study data collection procedures Patient followed in the department of internal medicine of CHU Lille Patient with one of the following autoimmune disease, defined according to international criteria: systemic lupus erythematosus, systemic sclerosis, Gougerot-Sjögren syndrome and idiopathic thrombocytopenic purpura Being socially insured Exclusion Criteria: Overlapping syndrome with another autoimmune disease Age ≤18 years Pregnant or nursing women People in emergencies Person incapable of consent Persons deprived of liberty Persons without social security cover

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patient<br> | Biological: Monoclonal anti-cd303 antibody<br>* Addition of monoclonal anti CD303 antibodies or not (control) on 2 blood samples of the same patient, to which 10 μl of CpG (20 μg / ml) are added in order to activate plasmacytoid Dendritic Cells and to induce the secretion of Type I interferons.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| in vitro determination of the level of type I interferons by immunoenzymatic ELISA method. |  | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| in vitro determination of the level of type I interferons by immunoassay ELISA (by type of MIA) |  | Baseline | 
| in vitro determination of the level of type I interferons by ELISA immunoassay method in patients treated or not with immunosuppressive or immunomodulatory treatment. |  | Baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Autoimmune Diseases, Plasmacytoid Dendritic Cells, Type I Interferons, Antibodies, Anti-CD303